{"id":61739,"date":"2025-08-18T16:05:28","date_gmt":"2025-08-18T14:05:28","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/medimpact-offers-low-cost-unbranded-ustekinumab-aekn-biosimilar-to-any-specialty-pharmacy-in-the-us\/"},"modified":"2025-08-18T16:05:28","modified_gmt":"2025-08-18T14:05:28","slug":"medimpact-offers-low-cost-unbranded-ustekinumab-aekn-biosimilar-to-any-specialty-pharmacy-in-the-us","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/medimpact-offers-low-cost-unbranded-ustekinumab-aekn-biosimilar-to-any-specialty-pharmacy-in-the-us\/","title":{"rendered":"MedImpact Offers Low Cost, Unbranded Ustekinumab-aekn Biosimilar to Any Specialty Pharmacy in the US"},"content":{"rendered":"
\n

SAN DIEGO–(BUSINESS WIRE)–MedImpact Holdings Inc. today announced that it will have access to an unbranded biosimilar ustekinumab-aekn at a significantly lower cost than the reference Stelara\u00ae<\/sup> (ustekinumab). The biosimilar, distributed by Anda, an affiliate of Teva Pharmaceuticals USA, Inc., will be available for direct purchase from MedImpact\u2019s preferred partner, Birdi, Inc., by any licensed specialty pharmacy.<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cToday, a drug\u2019s cost rises at each step in the supply chain,\u201d said Arpit Patel, MedImpact Senior Vice President of Trade Relations and Supply Chain. \u201cWe designed our unbranded strategy to bypass these costs to deliver far greater value to pharmacies and payers, and a more affordable treatment option for patients.\u201d<\/p>\n

\nAs specialty drug costs continue to rise and pharmacies continue to close, MedImpact\u2019s unbranded biosimilar strategy provides specialty pharmacies with a new sourcing option and access to lower prices. It also gives payers across healthcare\u2014and not just MedImpact clients\u2014greater flexibility, choice, and control over one of their greatest cost drivers.<\/p>\n

\nAs part of a broader move to reduce the industry\u2019s reliance on rebates and enhance price transparency, payers and members will gain access to the low cost at the point of sale.<\/p>\n

\nBy using an FDA-designated interchangeable biosimilar purchased from Anda, an affiliate of Teva Pharmaceuticals USA, Inc., a company with proven biosimilar expertise, this strategy is expected to drive increased physician prescribing and enhanced patient acceptance, and ultimately deliver meaningful cost savings.<\/p>\n

\n\u201cMedImpact\u2019s specialty strategy is deeply rooted in the principle that pharmacies, members, and payers should not have to compromise access for affordability, and this strategy delivers on that promise,\u201d said Patel. \u201cThe unbranded ustekinumab-aekn, an interchangeable biosimilar to the reference drug Stelara\u00ae<\/sup>, <\/sup>is the first of many products we will be providing to expand access, drive affordability, and transform the specialty drug market.\u201d<\/p>\n

\nThe unbranded ustekinumab-aekn biosimilar is expected to be available for purchase on January 01, 2026.<\/p>\n

\nTo learn more about the unbranded ustekinumab-aekn biosimilar, please contact info@medimpact.com<\/a>.<\/p>\n

\nAbout MedImpact<\/b><\/p>\n

\nSan Diego-based MedImpact Healthcare Systems, Inc. is the nation\u2019s largest independent health solutions, technology, and pharmacy benefit management provider. For 35 years, MedImpact has helped commercial and government healthcare payers improve member health, manage benefits, and reduce drug costs. Today, MedImpact serves more than 20 million members and processes more than $40 billion in pharmacy transactions annually. To learn more, visit us online<\/a>, follow us on LinkedIn<\/a>, or contact us at info@MedImpact.com<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nJennifer Kroll, jkroll@jwa.co<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO–(BUSINESS WIRE)–MedImpact Holdings Inc. today announced that it will have access to an unbranded biosimilar ustekinumab-aekn at a significantly lower cost than the reference Stelara\u00ae (ustekinumab). The biosimilar, distributed by Anda, an affiliate of Teva Pharmaceuticals USA, Inc., will be available for direct purchase from MedImpact\u2019s preferred partner, Birdi, Inc., by any licensed specialty … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61739","6":"format-standard","7":"category-industry"},"yoast_head":"\nMedImpact Offers Low Cost, Unbranded Ustekinumab-aekn Biosimilar to Any Specialty Pharmacy in the US - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/medimpact-offers-low-cost-unbranded-ustekinumab-aekn-biosimilar-to-any-specialty-pharmacy-in-the-us\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MedImpact Offers Low Cost, Unbranded Ustekinumab-aekn Biosimilar to Any Specialty Pharmacy in the US - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO–(BUSINESS WIRE)–MedImpact Holdings Inc. today announced that it will have access to an unbranded biosimilar ustekinumab-aekn at a significantly lower cost than the reference Stelara\u00ae (ustekinumab). The biosimilar, distributed by Anda, an affiliate of Teva Pharmaceuticals USA, Inc., will be available for direct purchase from MedImpact\u2019s preferred partner, Birdi, Inc., by any licensed specialty ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/medimpact-offers-low-cost-unbranded-ustekinumab-aekn-biosimilar-to-any-specialty-pharmacy-in-the-us\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-18T14:05:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250818969311\/en\/712871\/22\/MedImpact_Black_Web_L.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medimpact-offers-low-cost-unbranded-ustekinumab-aekn-biosimilar-to-any-specialty-pharmacy-in-the-us\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medimpact-offers-low-cost-unbranded-ustekinumab-aekn-biosimilar-to-any-specialty-pharmacy-in-the-us\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"MedImpact Offers Low Cost, Unbranded Ustekinumab-aekn Biosimilar to Any Specialty Pharmacy in the US\",\"datePublished\":\"2025-08-18T14:05:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medimpact-offers-low-cost-unbranded-ustekinumab-aekn-biosimilar-to-any-specialty-pharmacy-in-the-us\\\/\"},\"wordCount\":422,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medimpact-offers-low-cost-unbranded-ustekinumab-aekn-biosimilar-to-any-specialty-pharmacy-in-the-us\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250818969311\\\/en\\\/712871\\\/22\\\/MedImpact_Black_Web_L.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medimpact-offers-low-cost-unbranded-ustekinumab-aekn-biosimilar-to-any-specialty-pharmacy-in-the-us\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medimpact-offers-low-cost-unbranded-ustekinumab-aekn-biosimilar-to-any-specialty-pharmacy-in-the-us\\\/\",\"name\":\"MedImpact Offers Low Cost, Unbranded Ustekinumab-aekn Biosimilar to Any Specialty Pharmacy in the US - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medimpact-offers-low-cost-unbranded-ustekinumab-aekn-biosimilar-to-any-specialty-pharmacy-in-the-us\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medimpact-offers-low-cost-unbranded-ustekinumab-aekn-biosimilar-to-any-specialty-pharmacy-in-the-us\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250818969311\\\/en\\\/712871\\\/22\\\/MedImpact_Black_Web_L.jpg\",\"datePublished\":\"2025-08-18T14:05:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medimpact-offers-low-cost-unbranded-ustekinumab-aekn-biosimilar-to-any-specialty-pharmacy-in-the-us\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medimpact-offers-low-cost-unbranded-ustekinumab-aekn-biosimilar-to-any-specialty-pharmacy-in-the-us\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medimpact-offers-low-cost-unbranded-ustekinumab-aekn-biosimilar-to-any-specialty-pharmacy-in-the-us\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250818969311\\\/en\\\/712871\\\/22\\\/MedImpact_Black_Web_L.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250818969311\\\/en\\\/712871\\\/22\\\/MedImpact_Black_Web_L.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medimpact-offers-low-cost-unbranded-ustekinumab-aekn-biosimilar-to-any-specialty-pharmacy-in-the-us\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MedImpact Offers Low Cost, Unbranded Ustekinumab-aekn Biosimilar to Any Specialty Pharmacy in the US\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MedImpact Offers Low Cost, Unbranded Ustekinumab-aekn Biosimilar to Any Specialty Pharmacy in the US - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/medimpact-offers-low-cost-unbranded-ustekinumab-aekn-biosimilar-to-any-specialty-pharmacy-in-the-us\/","og_locale":"en_US","og_type":"article","og_title":"MedImpact Offers Low Cost, Unbranded Ustekinumab-aekn Biosimilar to Any Specialty Pharmacy in the US - Pharma Trend","og_description":"SAN DIEGO–(BUSINESS WIRE)–MedImpact Holdings Inc. today announced that it will have access to an unbranded biosimilar ustekinumab-aekn at a significantly lower cost than the reference Stelara\u00ae (ustekinumab). The biosimilar, distributed by Anda, an affiliate of Teva Pharmaceuticals USA, Inc., will be available for direct purchase from MedImpact\u2019s preferred partner, Birdi, Inc., by any licensed specialty ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/medimpact-offers-low-cost-unbranded-ustekinumab-aekn-biosimilar-to-any-specialty-pharmacy-in-the-us\/","og_site_name":"Pharma Trend","article_published_time":"2025-08-18T14:05:28+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250818969311\/en\/712871\/22\/MedImpact_Black_Web_L.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/medimpact-offers-low-cost-unbranded-ustekinumab-aekn-biosimilar-to-any-specialty-pharmacy-in-the-us\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/medimpact-offers-low-cost-unbranded-ustekinumab-aekn-biosimilar-to-any-specialty-pharmacy-in-the-us\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"MedImpact Offers Low Cost, Unbranded Ustekinumab-aekn Biosimilar to Any Specialty Pharmacy in the US","datePublished":"2025-08-18T14:05:28+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/medimpact-offers-low-cost-unbranded-ustekinumab-aekn-biosimilar-to-any-specialty-pharmacy-in-the-us\/"},"wordCount":422,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/medimpact-offers-low-cost-unbranded-ustekinumab-aekn-biosimilar-to-any-specialty-pharmacy-in-the-us\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250818969311\/en\/712871\/22\/MedImpact_Black_Web_L.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/medimpact-offers-low-cost-unbranded-ustekinumab-aekn-biosimilar-to-any-specialty-pharmacy-in-the-us\/","url":"https:\/\/pharma-trend.com\/en\/medimpact-offers-low-cost-unbranded-ustekinumab-aekn-biosimilar-to-any-specialty-pharmacy-in-the-us\/","name":"MedImpact Offers Low Cost, Unbranded Ustekinumab-aekn Biosimilar to Any Specialty Pharmacy in the US - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/medimpact-offers-low-cost-unbranded-ustekinumab-aekn-biosimilar-to-any-specialty-pharmacy-in-the-us\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/medimpact-offers-low-cost-unbranded-ustekinumab-aekn-biosimilar-to-any-specialty-pharmacy-in-the-us\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250818969311\/en\/712871\/22\/MedImpact_Black_Web_L.jpg","datePublished":"2025-08-18T14:05:28+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/medimpact-offers-low-cost-unbranded-ustekinumab-aekn-biosimilar-to-any-specialty-pharmacy-in-the-us\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/medimpact-offers-low-cost-unbranded-ustekinumab-aekn-biosimilar-to-any-specialty-pharmacy-in-the-us\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/medimpact-offers-low-cost-unbranded-ustekinumab-aekn-biosimilar-to-any-specialty-pharmacy-in-the-us\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250818969311\/en\/712871\/22\/MedImpact_Black_Web_L.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250818969311\/en\/712871\/22\/MedImpact_Black_Web_L.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/medimpact-offers-low-cost-unbranded-ustekinumab-aekn-biosimilar-to-any-specialty-pharmacy-in-the-us\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"MedImpact Offers Low Cost, Unbranded Ustekinumab-aekn Biosimilar to Any Specialty Pharmacy in the US"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61739","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61739"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61739\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61739"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61739"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61739"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}